|
Emergent’s CEO Discusses Q4 2012 Results – Earnings Call Transcript
Seeking Alpha In 2012, they initiated two exciting chemical trials for TRU-016 a Phase 1b study that combined TRU-016 with Rituximab in frontline CLL and a Phase 2 study that combines TRU with bendamustine in relapsed refractory CLL. We are very excited about the … |
|
Novartis’s Biosimilar Rituxan Is ‘On Track,’ Sandoz Head Says
Bloomberg Companies including Boehringer Ingelheim GmbH are racing to bring a biosimilar version of the drug, also known as rituximab, to the market. The original compound, sold by Roche Holding AG (ROG) and Biogen Idec Inc. (BIIB), had about $7 billion in sales … |
|
Roche’s Rituxan Cures Rare Skin-Blistering Disease in Study
Bloomberg “With one shot of rituximab we have a long-term result,” he said, using Rituxan’s generic name. Rituxan, approved as a treatment for lymphoma, leukemia and rheumatoid arthritis, had sales of 6.7 billion Swiss francs ($7.1 billion) last year, making it … |
|
SymBio Announces Completion of Patient Enrollment of TREAKISYM® (SyB L …
Marketwire (press release) This randomized trial is evaluating the combination of TREAKISYM® and rituximab versus R-CHOP 2. SymBio initiated this multicenter open-label Phase II trial as a line extension study for TREAKISYM® in November, 2011, in collaboration with Eisai. |
|
iBio adds new therapeutic antibody candidate to its pipeline
pharmabiz.com Prior to the discovery of this influenza antibody product candidate, the collaboration has produced rituximab and palivizumab biosimilar candidates. “We are pleased to further expand our antibody product candidate pipeline, particularly with an … |
|
IQWiG rejects Cell Therapeutics’ Pixuvri
PMLiVE Results from the PIX306 trial, comparing Pixuvri and Roche’s MabThera (rituximab) to a regimen of Lilly’s Gemzar (gemcitabine) and MabThera, are expected by June 2015 as part of this post-marketing follow-up. Conditional marketing authorisations are … |
|
iBio Adds New Therapeutic Antibody to Its Pipeline
PharmaLive (press release) (subscription) Prior to the discovery of this influenza antibody product candidate, the collaboration has produced rituximab and palivizumab biosimilar candidates. “We are pleased to further expand our antibody product candidate pipeline, particularly with an … |
|
German Institute for Quality and Efficiency in Health Care (IQWiG) Publishes …
The Herald | HeraldOnline.com The European Medicines Agency’s (the “EMA”) Committee for Medicinal Products for Human Use has accepted PIX306, CTI’s ongoing randomized controlled Phase 3 clinical trial, which compares PIXUVRI-rituximab to gemcitabine-rituximab in patients who … |
Business StandardRoche dropping Herceptin price in India by 30%FiercePharmaHe said Roche would drop the price of trastuzumab in India from its current 110,700 rupees ($2,000) to 75,000 rupees, a 31% drop. Rituximab would be reduced from about $1,456 a …
Cell Therapeutics Management Discusses Q4 2012 Results – Earnings Call …Seeking AlphaAs you may recall, this is a randomized trial of pixantrone-rituximab versus gemcitabine-rituximab in patients with aggressive B-cell NHL relapse after receiving CHO…